Novel oncolytic adenovirus-based PEPvIII vaccine displays a super antitumor effect in glioma models
Background
Currently, an epidermal growth factor receptor variant III (EGFRvIII)-specific peptide (PEPvIII) vaccine has not achieved satisfactory outcomes in several clinical trials for glioblastoma. This is probably due to the poor immunogenicity of …